Related Experiment Video
Updated: May 30, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Benzalkonium chloride in glaucoma medications
Robert Noecker1, Kimberly V Miller
1Ophthalmic Consultants of Connecticut, Fairfield, CT 06824, USA. robertnoecker@comcast.net
Abstract:
Benzalkonium chloride (BAK) is the preservative used most commonly in eye drops. Although it is effective as an antimicrobial and antifungal agent, both in vitro and in vivo studies have demonstrated adverse effects on surface epithelial cell populations. This is of particular concern with regard to topical medications used over long periods for chronic conditions, such as glaucoma. Newer non-BAK-containing drops are becoming increasingly available, providing an alternative for patients needing long-term eye drop therapy.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

